These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1165 related articles for article (PubMed ID: 4138077)

  • 1. Cell surface modification in the treatment of experimental cancer: neuraminidase or concanavalin A.
    Simmons RL; Rios A
    Cancer; 1974 Oct; 34(4 Suppl):suppl:1541-7. PubMed ID: 4138077
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuraminidase and concanavalin A in the experimental immunotherapy of cancer.
    Simmons RL; Rios A
    Johns Hopkins Med J Suppl; 1974; 3():75-84. PubMed ID: 4536589
    [No Abstract]   [Full Text] [Related]  

  • 3. Active specific immunotherapy of minimal residual tumor: excision plus neuraminidase-treated tumor cells.
    Rios A; Simmons RL
    Int J Cancer; 1974 Jan; 13(1):71-81. PubMed ID: 4818273
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative immunotherapeutic effect of concanavalin A and neuraminidase-treated cancer cells.
    Simmons RL; Rios A
    Transplant Proc; 1975 Jun; 7(2):247-51. PubMed ID: 1129845
    [No Abstract]   [Full Text] [Related]  

  • 5. Horizons in tumor immunology. A seminar.
    Wilson RE; Alexander P; Rosenberg SA; Simmons RL
    Arch Surg; 1974 Jul; 109(1):17-29. PubMed ID: 4834133
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative and combined effect of BCG and neuraminidase in experimental immunotherapy.
    Simmons RL; Rios A
    Natl Cancer Inst Monogr; 1973 Dec; 39():57-68. PubMed ID: 4595327
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunotherapy with neuraminidase-treated tumor cells after radiotherapy.
    Song CW; Levitt SH
    Radiat Res; 1975 Dec; 64(3):485-91. PubMed ID: 1197655
    [No Abstract]   [Full Text] [Related]  

  • 8. Neuraminidase treated cells and their role in cancer immunotherapy.
    Simmons RL; Rios A
    Birth Defects Orig Artic Ser; 1973 Mar; 9(2):223-8. PubMed ID: 4611534
    [No Abstract]   [Full Text] [Related]  

  • 9. Experimental and clinical trials with BCG immunotherapy.
    Sparks FC; Silverstein MJ; Hunt JS; O'Connell TX; Lee YT; Pilch YH; Haskell CM; Morton DL
    Johns Hopkins Med J Suppl; 1974; 3():103-20. PubMed ID: 4609024
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunospecific regression of various syngeneic mouse tumors in response to neuraminidase-treated tumor cells.
    Rios A; Simmons RL
    J Natl Cancer Inst; 1973 Aug; 51(2):637-44. PubMed ID: 4765377
    [No Abstract]   [Full Text] [Related]  

  • 11. Experimental cancer immunotherapy using a neuraminidase-treated non-viable frozen tumor vaccine.
    Rios A; Simmons RL
    Surgery; 1974 Apr; 75(4):503-7. PubMed ID: 4840798
    [No Abstract]   [Full Text] [Related]  

  • 12. Failure of immunotherapy with neuraminidase-treated tumor cell vaccine in mice bearing established 3-methylcholanthrene-induced sarcomas.
    Spence RJ; Simon RM; Baker AR
    J Natl Cancer Inst; 1978 Feb; 60(2):451-9. PubMed ID: 621758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combined effect of radiotherapy and neuraminidase-treated tumor cells on 3-methylcholanthrene-induced fibrosarcoma.
    So SK; Song CW; Rios A; Simmons RL
    J Surg Oncol; 1977; 9(6):527-40. PubMed ID: 592852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of cancer: immunospecific rejection of tumors in recipients of neuraminidase-treated tumor cells plus BCG.
    Simmons RL; Rios A
    Science; 1971 Nov; 174(4009):591-3. PubMed ID: 4940021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunospecific regression of methylcholanthrene fibrosarcoma using neuraminidase. 3. Synergistic effect of BCG and neuraminidase treated tumor cells.
    Simmons RL; Rios A
    Ann Surg; 1972 Aug; 176(2):188-94. PubMed ID: 4562008
    [No Abstract]   [Full Text] [Related]  

  • 16. Neuraminidase and regression of solid tumors.
    Lancet; 1972 Mar; 1(7749):523-4. PubMed ID: 4110025
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumor immunology with particular reference to malignant melanoma.
    Maguire HC
    Int J Dermatol; 1975; 14(1):3-11. PubMed ID: 1092622
    [No Abstract]   [Full Text] [Related]  

  • 18. Modifying the immunogenicity of cell membrane antigens. Tumors and transplants.
    Simmons RL; Rios A; Toledo-Pereyra LH; Steinmuller D
    Am J Clin Pathol; 1975 May; 63(5):714-34. PubMed ID: 1130323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunospecific regression of methylcholanthrene fibrosarcoma with the use of neuraminidase.
    Simmons RL; Rios A; Lundgren G; Ray PK; McKhann CF; Haywood GR
    Surgery; 1971 Jul; 70(1):38-46. PubMed ID: 5092115
    [No Abstract]   [Full Text] [Related]  

  • 20. Antitumour immunity--1. Differential response of neuraminidase-treated and x-irradiated tumour vaccine.
    Ray PK; Thakur VS; Sundaram K
    Eur J Cancer (1965); 1975 Jan; 11(1):1-8. PubMed ID: 1132396
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 59.